期刊
ONCOIMMUNOLOGY
卷 5, 期 9, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2016.1208876
关键词
Carboplatin; cisplatin; glioblastoma immunosuppression; glioblastoma; immunomodulation; immunotherapy; nanomedicine; nanoparticles; oxaliplatin; platinum-based chemotherapy
资金
- National Institutes of Health [K12NS080223, K25EB018370, K08NS09043]
- Institutional Research Grant of American Cancer Society [IRG-97-153-10]
- American Cancer Society [RSG-16-012-01-CDD]
- Passano Foundation Physician Scientist Award
- Elsa U. Pardee Foundation Research Grant
- PhRMA Foundation Research Starter Grant in Pharmaceutics
- AAPS Foundation New Investigator Grant Award
- Dean's Challenge Award to Accelerate Innovation and Discovery in Medicine
Glioblastoma (GBM) is a fatal brain cancer for which new treatment options are sorely needed. Platinum-based drugs have been investigated extensively for GBM treatment but few have shown significant efficacy without major central nervous system (CNS) and systemic toxicities. The relative success of platinum drugs for treatment of non-CNS cancers indicates great therapeutic potential when effectively delivered to the tumor region(s). New insights into the broad anticancer effects of platinum drugs, particularly immunomodulatory effects, and innovative delivery strategies that can maximize these multi-modal effects and minimize toxicities may promote the re-purposing of this chemotherapeutic drug class for GBM treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据